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Abstract
Aims/hypothesis Mitochondrial DNA (mtDNA) mutations
cause several diseases, including mitochondrial inherited
diabetes and deafness (MIDD), typically associated with the
mtDNA A3243G point mutation on tRNALeu gene. The
common hypothesis to explain the link between the genotype
and the phenotype is that the mutation might impair
mitochondrial metabolism expressly required for beta cell
functions. However, this assumption has not yet been tested.
Methods We used clonal osteosarcoma cytosolic hybrid cells
(namely cybrids) harbouring mitochondria derived from
MIDD patients and containing either exclusively wild-type
or mutated (A3243G) mtDNA. According to the importance
of mitochondrial metabolism in beta cells, we studied the
impact of the mutation on key parameters by comparing
stimulation of these cybrids by the main insulin secretagogue
glucose and the mitochondrial substrate pyruvate.
Results Compared with control mtDNA from the same
patient, the A3243G mutation markedly modified metabolic
pathways leading to a high glycolytic rate (2.8-fold increase),
increased lactate production (2.5-fold), and reduced glucose
oxidation (−83%). We also observed impaired NADH
responses (−56%), negligible mitochondrial membrane po-
tential, and reduced, only transient ATP generation.Moreover,
cybrid cells carrying patient-derived mutant mtDNA exhibited
deranged cell calcium handling with increased cytosolic loads
(1.4-fold higher), and elevated reactive oxygen species (2.6-
fold increase) under glucose deprivation.
Conclusions/interpretation The present study demonstrates
that the mtDNA A3243G mutation impairs crucial meta-
bolic events required for proper cell functions, such as
coupling of glucose recognition to insulin secretion.
Keywords A3243G tRNALeu gene . ATP. Calcium .
Diabetes . MIDD .Mitochondrial DNA .
Mitochondrial metabolism . ROS
Abbreviations
ANT adenine nucleotide translocator
ΔΨm mitochondrial membrane potential
FCCP carbonyl cyanide p-trifluoromethoxyphenyl-
hydrazone
KRBH KRB bicarbonate HEPES buffer
M12 patient-derived mutated mtDNA
MIDD mitochondrial inherited diabetes and deafness
(MIDD)
MnSOD manganese superoxide dismutase (also SOD2)
mtDNA mitochondrial DNA
rho° depleted of mtDNA
ROS reactive oxygen species
SOD1 copper zinc superoxide dismutase
W20 patient-derived wild type mtDNA
Introduction
Mitochondria carry their own genome in the form of
circular mitochondrial DNA (mtDNA) with only 37 genes
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(16,569 bp) encoding 13 polypeptides, 22 tRNAs and 2
ribosomal RNAs [1]. Mitochondrial protein biogenesis is
determined by nuclear and mitochondrial genomes, and
the few polypeptides encoded by the mtDNA are all
subunits of complexes involved in oxidative phosphory-
lation on the electron transport chain [2]. Mutations in the
mtDNA cause rare but debilitating human diseases [1],
including mitochondrial inherited diabetes and deafness
(MIDD). MIDD is often associated with the mtDNA
A3243G point mutation on the tRNALeu gene [1, 3–5],
usually in heteroplasmic form, i.e. a mixture of wild-type
and mutant mtDNA in patient cells. The mtDNA mutation
at position 3243 is associated with complex-1 deficiency
[6] and impaired respiratory chain activity [7]. Typically,
mitochondrial diabetes is clinically manifested during
adulthood before the age of 70 and can be differentiated
from monogenic MODY due to maternal transmission,
often in combination with bilateral hearing impairment
[8]. The pathogenicity of this mutation is hardly detect-
able in the endocrine pancreas [9, 10]. Moreover,
pancreatic islets of such patients may carry a low
heteroplasmy percentage of the A3243G mutation, com-
pared to other tissues [9].
Mitochondria play a key role in metabolism-secretion
coupling in pancreatic beta cells, primarily through
production of ATP. Elevation of the ATP:ADP ratio leads
to closure of the KATP-channels with subsequent rise in
cytosolic Ca2+ levels, ultimately triggering insulin secre-
tion [11]. Moreover, mitochondrial metabolism generates
coupling factors that participate in the sustained second
phase of the secretory response [12]. To date, the putative
impact of the A3243G mutation on insulin secretion in
diabetic patients has been examined in only a few studies,
where carriers of the mutation exhibited markedly reduced
insulin release in intravenous glucose tolerance tests and
hyperglycaemic clamps compared to non-carriers [13–15].
It was hypothesised that a defect in glucose recognition
would be an early possible primary abnormality in carriers
of the mutation [13]. It has been suggested that impaired
mitochondrial metabolism in cells of individuals carrying
mutations in the mitochondrial genome might predispose
to beta cell dysfunction, although this hypothesis has not
been tested [16]. The current hypothesis suggests that the
mitochondrial A3243G mutation could result in mito-
chondrial impairment leading to beta cell dysfunction.
Therefore, it is crucial to investigate the consequences of
this mutation on parameters highly relevant for beta cell
metabolism-secretion coupling.
Direct investigation of beta cell functions carrying
specific mtDNA mutations was technically impossible
since (1) unlike genomic DNA, mtDNA manipulations
are not feasible; (2) generation of cybrids with human
beta cells was ruled out as human beta cell lines were
unavailable at the time of our study; and (3) it is not
possible to mix human mitochondria with rodent genomic
DNA (e.g. with existing rodent beta cell lines). Accord-
ingly, we studied patient-derived mitochondria in a
human osteosarcoma cell line. Specifically, cells obtained
from the parental human cell line 143B and depleted of
mtDNA (rho°) were used as recipients for mtDNA from a
patient with the A3243G mutation. The resulting clonal
cell lines contained either exclusively patient-derived
mutated mtDNA (M12 cells) or wild-type mtDNA (W20
cells) from the same patient [7]. In these cells, key
metabolic parameters in response to glucose versus the
mitochondrial substrate pyruvate were measured.
Materials and methods
Cell culture
We used clonal cybrid cell lines derived from mtDNA-free
ρ° cells replenished with M12 or W20 following cytosolic
hybrid-based transformation [7]. The cybrid cell lines
143B. TK− (143B), βρ°-3 (rho°), W20, and M12 were
cultured in DMEM (Gibco Invitrogen, Scotland, UK)
containing 4.5 mg/ml of glucose and supplemented with
110 μg/ml pyruvate, 50 μg/ml uridine, 5% heat-inactivated
FCS and antibiotics. The cells were routinely analysed for
the presence of mutated mtDNA by PCR using total DNA
[7]. For experiments, cells were seeded in 24-well plates
and cultured 3 to 4 days before use. Reagents commonly
used for the experiments were from Sigma–Aldrich (Buchs,
Switzerland).
Glucose metabolism and lactate production
Glucose utilisation and oxidation were measured in cybrid
cells essentially as previously described [17]. For glucose
utilisation, cells were incubated for 10 min in KRB
bicarbonate HEPES buffer (KRBH) containing in mmol/l:
135 NaCl, 3.6 KCl, 10 HEPES (pH 7.4), 5 NaHCO3, 0.5
NaH2PO4, 0.5 MgCl2, 1.5 CaCl2, and supplemented with
5 mmol/l glucose traced with D-[5-3H]glucose (final
specific activity 14.8 MBq/mmol), then stopped on ice.
Supernatants were collected, centrifuged to remove de-
tached cells, and 3H2O separated from D-[5-
3H]glucose
using Dowex columns. For glucose oxidation, cells were
incubated for 1 h in KRBH containing 5 mmol/l glucose
traced with D-[14-C(U)]glucose (final specific activity
1.85 MBq/mmol), then stopped by HCl addition before
trapping of CO2 overnight in papers soaked with phenyl-
thylamine:methanol (1:1). Respective 3H2O and
14CO2
productions were counted in a liquid scintillation counter
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(LS6500: Beckman Instruments, Palo Alto, CA, USA).
Proteins were determined and glucose utilisation and
oxidation expressed as nmol per mg protein per hour. The
concentration of 5 mmol/l glucose for stimulations was
selected throughout the study according to the dose
response exhibited by these cells. Metabolic parameters
were measured following cell preincubation in glucose-free
medium for 2 h.
Cybrid cells were cultured in 24-well plates in
complete culture medium for 48 h. Afterwards, culture
medium serum was reduced from 5 to 1% and, after
48 h of culture, media were collected to measure lactate
release. Lactate concentrations were determined as
described [17].
Cellular reactive oxygen species
Cellular reactive oxygen species (ROS) were measured
after cell preincubation in glucose-free or glucose
10 mmol/l medium for 6 h in a 24-well plate. The
cells were then incubated in glucose-free KRBH
containing 10 μmol/l of the ROS-sensitive probe CM-
H2DCFDA (Molecular Probes, Eugene, OR, USA) for
20 min. Quantification of CM-H2DCFDA fluorescence
was estimated as the slope normalised for protein content.
Fluorescence was monitored with excitation and emission
filters set at 485 nm and 520 nm, respectively, in a plate-
reader fluorimeter (Fluostar Optima; BMG Labtechnolo-
gies, Offenburg, Germany).
Quantitative real-time PCR
Total RNA was extracted using a kit (RNeasy Mini;
Qiagen, Hilden, Germany) and 2 μg RNA were converted
into cDNA as previously described [18]. Primers for the
reference genes beta-actin, copper zinc superoxide dis-
mutase (CuZnSOD, also known as SOD1) and manganese
superoxide dismutase (MnSOD, also known as SOD2)
were designed using Primer Express (Applied Biosystems,
Foster City, CA, USA). The primer sequences were:
hCuZnSOD: forward 5′-CAGGGCATCATCAATTTCGA-
3 ′ , reverse 5 ′ -CCATGCAGGCCTTCAGTCA-3 ′ ;
hMnSOD: forward 5′-GCTTGTCCAAATCAGGATCCA-
3′, reverse 5′-TAGTAAGCGTGCTCCCACACA-3′; hbeta-
actin: forward 5 ′-GACAGGATGCAGAAGGAGAT
TACT-3′, reverse 5′-TGATCCACATCTGCTGGAAGGT-
3′. Quantitative RT-PCR was performed using an sequence
detection system (ABI 7000; Applied-Biosystems) and
PCR products were quantified fluorometrically using the
SYBR Green Core Reagent kit (Stratagene, La Jolla, CA,
USA). Sod1 and Sod2 mRNA values were normalised for
beta-actin gene. Experiments were performed in triplicate
for each cell type.
NAD(P)H measurements and mitochondrial
membrane potential
NAD(P)H levels were measured in attached cells as
described [19]. Cells were placed in a plate reader
fluorimeter at 37°C with automated injectors for test
compounds and stimulated as indicated following stabilisa-
tion of the signal for 10 min in glucose/pyruvate-free
KRBH. Maximal fluorescence changes were recorded after
adding a mixture of 5 μmol/l rotenone (electron transport
chain complex-1 inhibitor) plus 2 μmol/l antimycin-A
(electron transport chain complex-3 inhibitor).
The mitochondrial membrane potential (ΔΨm) was
monitored as fluorescence in cells loaded for 20 min with
10 μg/ml rhodamine-123 as described [19]. Glucose
(5 mmol/l) or pyruvate (1 mmol/l) and the protonophore
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
(FCCP, 1 μmol/l) were added at the indicated times.
Cytosolic ATP levels and total cellular ATP content
Cytosolic ATP levels were monitored in cybrid cells
expressing the ATP-sensitive bioluminescent probe lu-
ciferase, 1 day after transduction with the specific
AdCAG-Luc viral construct [20, 21], in luminometer
plate-reader as described [19]. After 5 min in glucose-
free KRBH, cells were stimulated with 5 mmol/l glucose
or 1 mmol/l pyruvate, and 2 mmol/l NaN3 were added at
the end as a mitochondrial poison. Total ATP contents
were also determined in cybrid cell lysates after 5 min
glucose (5 mmol/l) or pyruvate (1 mmol/l) stimulation,
using an ATP bioluminescent assay kit (Roche,
Mannheim, Germany).
Calcium concentration measurements
Cytosolic calcium changes were monitored as ratiometric
measurements of Fura-2 fluorescence from cells placed in a
plate-reader fluorimeter as described [22]. To measure
mitochondrial calcium, cells cultured in 24-well plates for
3 to 4 days were transduced with AdCA-mAeq adenovirus
enabling expression of the Ca2+-sensitive photoprotein
aequorin targeted to the mitochondria. Twenty hours after
viral treatment, cells were loaded with the aequorin
prosthetic group coelenterazine (2.5 μmol/l) in KRBH for
1 h and luminescence was monitored in the plate-reader
luminometer [19].
Statistical analysis
Unless otherwise indicated, data are means ± SE for at least
three independent experiments. Differences between groups
were assessed by the Student’s t-test.
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Results
Glucose metabolism and lactate production
Glucose utilisation, i.e. glycolytic rate, was measured as the
formation of 3H2O from D-[5-
3H]glucose at the glycolysis
enolase step (Fig. 1). On 5 mmol/l glucose stimulation, rho°
cells consumed 1.9 times more glucose than parental 143B
cells (p<0.05). This elevated glucose utilisation was
accompanied by acidification of the culture medium. Thus,
after 48 h incubation in complete culture medium, rho°
cells generated 3.3 times more lactate than 143B cells
(p<0.01) (Fig. 1b).
Analysis of cybrid cells showed a 2.8-fold increase
(p<0.05) of glucose utilisation in M12 versus W20 cells
(Fig. 1c). Glucose oxidation in control W20 cells accounted
for 49% of the glycolytic rate. Glucose oxidation was much
lower in M12 than in W20 cells (−83%, p<0.05) and
accounted for only 3.5% of the glycolytic rate in M12 cells.
Accordingly, lactate generation was elevated in M12
compared to W20 cells (2.5-fold, p<0.05) (Fig. 1d). We
have previously reported a marked increase in the ratio of
lactate to pyruvate production by M12 cells [7], and
together these data demonstrate that the A3243G mutation
renders cells highly glycolytic with preferred lactate release
rather than pyruvate oxidation by mitochondria.
Cellular ROS and SOD expression
Cybrid cells were incubated in glucose-free or glucose
10 mmol/l medium for 6 h and intracellular ROS were
measured using CM-H2DCFDA probe. We observed no
significant differences in ROS generation between rho° and
143B cells (not shown).
In contrast, mutant M12 cells generated 2.1 times more
intracellular ROS than W20 in the absence of glucose
(p<0.05) (Fig. 2a). However, no significant differences in
ROS generation were found between mutant M12 and W20
cells upon glucose (10 mmol/l) stimulation (not shown). In
M12 cells incubated with 10 mmol/l glucose, intracellular
ROS levels fell by 32% (p<0.005) against the glucose-
deprived state (Fig. 2b).
Expression of key enzymes modulating cellular ROS at
the cytosolic (SOD1) and the mitochondrial (SOD2) levels
Fig. 1 Glucose utilisation and lactate production in cybrid cells.
mtDNA-depleted (rho°) cells were compared to parental 143B cells
(a, b) and mtDNA mutant (M12) cells to wild type (W20) cells (c, d).
Glucose (5 mmol/l) utilisation (a, c) was measured as the formation of
3H2O from D-[5-
3H]glucose over a 10-min stimulation period and
glucose oxidation (c) as the production of 14CO2 from D[14-C(U)]
glucose over a 1-h incubation period. Lactate production (b, d) was
determined in the media following a 48-h culture period. Values are
means + SE of four independent experiments (*p<0.05; **p<0.01)
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was analysed by quantitative RT-PCR. Mitochondrial
SOD2 mRNA levels were 1.36±0.02 fold higher in W20
than in M12 cells (p<0.01). No difference was seen in
cytosolic SOD1 mRNA levels between W20 and M12 cells
(Fig. 2c).
NAD(P)H levels
NAD(P)H levels are predominantly determined by mito-
chondria in healthy cells. Glucose (5 mmol/l) stimulation
raised NAD(P)H levels in control W20 and parental 143B
cells. Conversely, glucose failed to efficiently promote
NAD(P)H generation in M12 and rho° cells (Fig. 3a,b).
Average NAD(P)H levels during the 5 min after glucose
addition were 56% lower in M12 than in W20 cells
(p<0.0001), and 51% lower in rho° than in 143B cells
(p<0.0002).
The mitochondrial substrate pyruvate (1 mmol/l) raised
NAD(P)H levels in W20 and 143B cells, whereas in M12
and rho° cells it lowered NAD(P)H (Fig. 3c,d). Blockade of
the respiratory chain at complex-1 (5 μmol/l rotenone) and
complex-3 (2 μmol/l antimycin A), added to maximally
increase mitochondrial NADH, further enhanced autofluo-
rescence, revealing the mitochondrial origin of the signal.
These results show that mtDNA mutant cells exhibit
deranged redox state and are unable to elevate NAD(P)H
above basal levels.
Mitochondrial membrane potential
In control W20 and 143B cells, the protonophore FCCP
dissipated, thereby revealing, established resting ΔΨm. In
contrast, FCCP addition in mutant M12 and rho° cells
showed that resting ΔΨm in these cells was only negligible
(Fig. 4a). Upon glucose (5 mmol/l) stimulation, hyper-
polarisation was observed in the four cell lines.
Interestingly, ΔΨm was also built up on glucose
stimulation in M12 and rho° cells, although responses were
slower than in respective controls (Fig. 4b,c). Upon
pyruvate (1 mmol/l) stimulation, the paradoxical effect of
a first-phase depolarisation was observed in 143B cells
(Fig. 4d). This effect has been previously attributed to
pyruvate uptake by mitochondria and is followed by the
expected sustained hyperpolarisation [18]. Unlike glucose
stimulation, the mitochondrial substrate pyruvate did not
increase ΔΨm in M12 or rho° cells (Fig. 4d).
Next, using inhibitors of the ATP synthase and of the
adenine nucleotide translocator (ANT), we investigated the
mechanisms underlying the delayed glucose-induced mito-
chondrial hyperpolarisation in M12 and rho° cells. Previous
studies attributed the build up of ΔΨm in rho° cells to
reverse activities of ATP synthase and ANT, thereby
favouring the electrogenic exchange of ATP4− for ADP3−
[2, 23]. However, this effect has not yet been characterised
in cells containing mtDNA mutations. The ATP synthase F0
section is composed of two mtDNA encoded subunits and
is not fully active in mtDNA mutant cell lines or in rho°
cells [2, 23]. In contrast, ATP synthase F1 section activity is
preserved in rho° cells where it may function in the reverse
mode, i.e. as an ATPase. To pinpoint the origin of glucose-
induced ΔΨm in M12 cells, specific blockers of F0 and F1
ATPase subunits were used: oligomycin (2 μg/ml) and
aurovertin (30 or 60 μmol/l), respectively. Oligomycin did
Fig. 2 Reactive oxygen species (ROS) in cybrid cells. ROS
production was measured using the probe CM-H2DCFDA following
6 h of incubation in the absence or presence of glucose. a W20 and
M12 ROS levels with no glucose. M12 ROS levels (b) in the absence
(No glc) or presence (Glc) of glucose 10 mmol/l. Values are means +
SE of three independent experiments (*p<0.05). c SOD1 and SOD2
mRNA levels in W20 (dark bars) and M12 (shaded bars) cells were
normalised for beta-actin expression. Values in arbitrary units (AU) are
means + SE of three independent experiments done in triplicate
(**p<0.01)
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not prevent glucose-evoked ΔΨm in M12 cells and rho°
cells (data not shown). However, aurovertin (60 μmol/l) in
combination with bongkrekic acid (10 μmol/l), an ANT
inhibitor acting on the matrix side, fully prevented glucose-
induced ΔΨm establishment in M12 and rho° cells (Fig. 5a,
b). These results indicate that glucose-induced mitochon-
drial hyperpolarisation observed in M12 cells was generat-
ed by combined reverse activities of ANT and ATP
synthase.
Cellular ATP levels
In control W20 and parental 143B cells, glucose (5 mmol/l)
stimulation resulted in sustained elevation of cytosolic ATP
levels, which were disrupted by adding the mitochondrial
poison NaN3 (Fig. 6a,c). In mutant M12 and rho° cells,
ATP generation upon glucose stimulation was only tran-
sient, as a drop in ATP levels was observed before NaN3
addition (Fig. 6b,d). The mitochondrial substrate pyruvate
(1 mmol/l) augmented cytosolic ATP levels in W20 and
143B cells (Fig. 6a,c), but not in M12 and rho° cells
(Fig. 6b,d). This shows that ATP generation in M12 cells,
as in rho° cells, was exclusively dependent on glucose
utilisation, with no contribution by mitochondria.
Upon pyruvate stimulation, an initial drop in ATP levels
occurred in W20 and 143B cells before sustained ATP
increase (Fig. 6a,c), an effect correlating with transient
depolarisation of ΔΨm [18]. Measurements of total cellular
ATP concentrations showed that pyruvate stimulation did
not change ATP contents in M12 or rho° cells, indicating
the lack of ATP generation of mitochondrial origin in these
cells (not shown).
Basal absolute ATP contents in rho° and M12 cells were
222 and 100 times lower than in 143B or W20 cells,
respectively, i.e. 0.09±0.04 (rho°), 0.17±0.08 (M12), 20.0±
4.2 (143B) and 17.2±4.0 (W20) nmol ATP/mg protein
(Fig. 7). Following 5 min glucose (5 mmol/l) stimulation,
ATP contents in these cells were: 9.7±1.6 (rho°), 12.5±2.0
(M12), 24.0±5.1 (143B) and 20.7±5.8 (W20) nmol ATP/mg
protein (Fig. 7). Therefore, the following fold increases in
cellular ATP contents upon glucose stimulation were: 1.2-
fold (143B), 1.2-fold (W20), 108-fold (rho°), and 74-fold
(M12). ATP contents measured in M12 and rho° cells,
before and after glucose stimulation, were consistent with
Fig. 3 Effects of glucose (Glc) and pyruvate (Pyr) on NAD(P)H
levels in cybrid cells. W20 (bold lines) and M12 (thin lines) cells (a,
c) or (b,d) 143B (bold lines) and rho° (thin lines) cells were kept in
glucose-free KRBH for the first 10 min and then stimulated with
5 mmol/l glucose (a,b) or 1 mmol/l pyruvate (c,d) as indicated by the
arrows. In order to maximally elevate mitochondrial NADH levels, a
mixture of inhibitors of complex-1 (5 μmol/l rotenone; Ro) and
complex-3 (2 μmol/l antimycin A; AA) was added 10 min after
pyruvate stimulation. Values in arbitrary units (AU) are means + SE of
three independent experiments (**p<0.001)
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the kinetics of cytosolic ATP levels. These results show that
A3243G mutation renders cells exclusively dependent on
glycolysis for the supply of cellular ATP.
Calcium concentrations
Cytosolic calcium rises were evoked by adding the inositol-
1,4,5-triphosphate agonist histamine (100 μmol/l), trigger-
ing calcium mobilisation from the endoplasmic reticulum.
Histamine induced calcium peaks of similar amplitudes in
M12 and W20 cells. However, return to basal levels during
the second phase was markedly delayed in mutant M12,
resulting in elevated cytosolic calcium load (Fig. 8a).
Cytosolic calcium loads, determined for 2 min after the
peak and expressed as the AUC, were 1.4-fold higher
(p<0.005) in M12 than in W20 cells.
Mitochondria participate in cellular calcium homeostasis
through their ability to buffer and redistribute calcium.
Mitochondrial calcium levels were monitored in M12 and
W20 cells expressing the calcium-sensitive photoprotein
aequorin targeted to mitochondria. Qualitatively, M12 and
control W20 cells exhibited similar mitochondrial calcium
patterns in terms of histamine responses However, calcium
levels were shifted down in M12 cells, indicating reduced
calcium uptake by mitochondria (Fig. 8b).
Discussion
This study demonstrates that the diabetes-associated
A3243G mutation in the mitochondrial genome impairs
the key metabolic events required for cellular functions,
such as metabolism-secretion coupling. Due to technical
limitations, the study was performed in non-beta cells, i.e.
in an osteosarcoma cell line. A recently established human
beta cell line [24] might enable the establishment of beta
cell cybrids in future. To investigate the putative link
between the specific mtDNA mutation A3243G and
cellular metabolism, it was crucial to study side-by-side
cybrid cells carrying either mutant or wild type mtDNA
obtained from the same patient. We observed that the
A3243G mutation induced a shift to dominantly glycolytic
metabolism, as M12 cells consumed more glucose and
produced more lactate than W20 cells, while glucose
oxidation to CO2 was reduced. The mitochondrial mutation
not only affected mitochondrial metabolism, but also
modified cytosolic calcium homeostasis.
In response to glucose addition, levels of reducing
equivalents in the form of NAD(P)H were not further
elevated in mutant M12 cells compared with basal levels. In
contrast, sustained increases in NAD(P)H levels were
observed upon glucose stimulation in control W20 cells.
These results reflect the impact of this mutation on the
electron transport chain. Indeed, complex-1 activity in M12
cells is known to be diminished in comparison to W20 cells
[7], a finding confirmed in this study by the lack of
responses to complex-1 inhibitor rotenone. The associated
deficient NADH reoxidation would lead to mitochondrial
NADH accumulation, slowing down reactions coupled to
NADH generation in the citric acid cycle. The metabolic
consequences would be a switch to anaerobic glucose
Fig. 4 Mitochondrial membrane
potential (ΔΨm) in cybrid cells.
The four different cell lines
(143B, rho°, W20, M12) were
cultured in 24-well plates and
ΔΨm was monitored as rhoda-
mine-123 (Rh-123) fluores-
cence. a After 20 min of
stabilisation, the amplitude of
resting ΔΨm was estimated fol-
lowing complete dissipation of
the proton gradient by the
addition of 1 μmol/l of the
protonophore carbonyl cyanide
p-trifluoromethoxyphenylhydra-
zone (FCCP). For glucose (Glc)
(b, c) and pyruvate (Pyr)
(d) responses, cells were kept in
nutrient-free KRBH for the first
10 min before stimulation with
5 mmol/l glucose or 1 mmol/
l pyruvate. Ten minutes after
stimulation, ΔΨm was collapsed
by adding 1 μmol/l FCCP.
Values in arbitrary units (AU)
are means + SE of three to eight
independent experiments
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utilisation accompanied by increased lactate generation,
both observed in the present study. Interestingly, NADH
levels were transiently reduced in mutant M12 cells upon
pyruvate stimulation, an effect attributed to favoured
metabolism through lactate dehydrogenase rather than
mitochondrial pathway.
Established ΔΨm, as measured in control W20 cells, was
absent in mutant M12 cells, revealing that the A3243G
mutation carried by M12 cells severely impaired the
electron transport chain activity, in accordance with reduced
activities of mtDNA-encoded complexes 1, 3, and 4 of the
electron transport chain in M12 cells [7]. Interestingly,
some mitochondrial hyperpolarisation was observed in M12
cells upon glucose stimulation, albeit delayed in compari-
son to control W20 cells. Our data indicate that this effect
results from inverted activities of ANT, in this case
importing cytosolic ATP, and from ATP synthase working
as ATPase, i.e. hydrolysing instead of synthesising ATP [2].
This metabolic adaptation was demonstrated here by
inhibiting the translocator and the ATPase F1 subunit,
thereby abolishing M12 mitochondrial hyperpolarisation.
Even when not coupled to oxidative phosphorylation, the
build up of some ΔΨm is necessary for import of nuclear
encoded proteins in mitochondria, where major metabolic
pathways have to interact. Therefore, these mutant cells rely
on glycolysis-derived ATP that enters mitochondria to be
hydrolysed to ADP + H+. ADP is then exported from the
mitochondria and the overall process produces net negative
charges in the mitochondrial matrix, promoting hyper-
polarisation. Upon pyruvate stimulation, no build up of
ΔΨm was seen in M12 cells, indicating the absolute
requirement of glycolytic pathway.
Mutant M12 cells exhibited severe reduced ATP contents
compared with W20 cells. Surprisingly, we observed
massive increases in ATP levels in M12 cells upon glucose
stimulation, although these were only transient and barely
approaching basal absolute ATP levels in control W20
cells. In M12 cells, the lack of response to pyruvate
stimulation and to azide-mediated inhibition showed the
impairment of mitochondria as ATP generators, pointing to
glycolysis as the source of cellular ATP. Together with the
increased glycolytic rate, these results show a remarkable
adaptation of cells with mutated mtDNA, enabling them to
generate ATP at the expense of glucose-derived carbons in
the form of lactate release. It is well known that such a
phenotype dramatically impairs glucose-stimulated insulin
secretion in beta cells.
Cytosolic Ca2+ rises evoked by histamine stimulation
were immediate and of similar amplitudes in control W20
and mutant M12 cells. However, the second phase,
corresponding to progressive return to basal levels, was
prolonged in M12 cells. Scarce ATP supply in mutant M12
cells possibly would not suffice for efficient Ca2+ transfer
into Ca2+ stores, i.e. the endoplasmic reticulum, by the
sarco(endo)plasmic-reticulum Ca2+-ATPase pump. Depo-
larised mitochondria in M12 cells might also help impair
Ca2+ buffering capacity of the cell. Accordingly, we
measured lower mitochondrial Ca2+ concentrations in
M12 than in W20 cells. Deranged Ca2+ homeostasis may
vary according to specific mtDNA mutations. In cybrid
cells with the T8356C mtDNA mutation, which is
associated with myoclonic epilepsy with ragged-red fibres
[25], mitochondrial Ca2+ homeostasis is also altered [26].
However, in contrast to A3243G cybrids, T8356C cells
exhibit normal cytosolic Ca2+ responses. Such a difference
might contribute to mtDNA-specific phenotypes.
Mitochondria are known to be the main source and target
of intracellular ROS. The imbalance between excessive
formation of ROS and limited antioxidant defences causes
oxidative stress [27]. Only few studies have looked at ROS
generation in cells with mtDNA mutations [28–30]. It is
Fig. 5 Glucose-induced mitochondrial membrane potential (ΔΨm) in
mutant M12 cells (a) and mtDNA-deficient (rho°) cells (b). Cells were
cultured in 24-well plates and ΔΨm was monitored as rhodamine-123
(Rh-123) fluorescence (arbitrary units [AU]). Cells were preincubated
for 30 min before the experiment in glucose-free KRBH without
(control, bold lines) or with a mixture containing 60 μmol/l aurovertin
and 10 μmol/l bongkrekic acid (Bo+Au, thin lines). During the
recordings, cells were kept in the same solutions for 10 min before
stimulation with 5 mmol/l glucose (Glc). Ten minutes after stimula-
tion, ΔΨm was collapsed by adding 1 μmol/l carbonyl cyanide
p-trifluoromethoxyphenylhydrazone (FCCP). Traces are one repre-
sentative of at least three independent experiments
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debatable whether mtDNA-depletion in rho° cells generates
more ROS than control cells would [31–34]. In the present
study, the A3243G mutation was associated with higher
intracellular ROS levels than control cells when glucose was
removed from the medium. Addition of 10 mmol/l glucose
lowered ROS levels in mutant M12 cells. Interestingly,
cytotoxicity has been reported in the absence of glucose in
cells carrying the A3243G mtDNA mutation [29]. Upon
glucose deprivation, ATP synthesis, normally compensated
by oxidative phosphorylation, is inefficient in mtDNA
mutants (Fig. 7a) due to defective electron transport chain
activity [7]. This lacking adaptability to other fuel sources
would induce metabolic stress leading to inefficient detox-
ification pathways and increased ROS, as proposed recently
[29]. Moreover, the observed lower expression of SOD2 in
M12 mutant cells, similarly to LHON cybrids [35], would
worsen the situation regarding ROS levels.
Upon glucose provision, ROS levels in M12 mutant cells
fell to levels comparable with W20 control cells. It has been
reported that cybrid cells carrying mutant mtDNA exhibit
increased [28, 30] or unchanged [29] ROS levels. In a
mouse model accumulating mtDNA mutations with age,
amounts of ROS were normal, despite severe respiratory
chain dysfunction [36]. Together, these findings indicate
that ROS generation in cells with mtDNA mutations might
not necessarily be altered pending compensatory energy
state.
Numerous studies at the cellular level found that
mitochondrial activation is crucial in beta cells for proper
coupling of nutrient metabolism to insulin secretion [12].
At the clinical level, the importance of mitochondrial
function in glucose homeostasis is revealed by diabetes-
associated mutations in the mitochondrial genome [4, 5, 10,
37]. As the aetiology of diabetes may not be primarily
Fig. 7 Total ATP concentrations in cybrid cells. Total cellular ATP
contents were determined in W20 and M12 cells (a) and 143B and
rho° cells (b) cells following 5 min stimulation with 5 mmol/l glucose
(grey bars), and normalised to cellular protein concentrations. Black
bars, no glucose. Values are means + SE of three independent
experiments (*p<0.05)
Fig. 6 Cytosolic ATP changes
in cybrid cells. Cytosolic ATP
levels were monitored as biolu-
minescence following luciferase
expression in wild-type mtDNA
W20 cells (a), mutant mtDNA
M12 cells (b), parental 143B
cells (c), and mtDNA-deficient
rho° cells (d). Cells were kept in
glucose-free KRBH for the first
5 min and then stimulated with
5 mmol/l glucose (black lines)
or 1 mmol/l pyruvate (dark grey
lines) for 10 min before abro-
gating ATP generation by the
addition of 2 mmol/l NaN3.
Light grey lines, no glucose.
Values are means + SE of three
to five independent experiments
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associated with beta cells, the putative link between
mtDNA mutations and beta cell dysfunction remains
hypothetical [16]. However, three indirect lines of evidence
suggest such a relationship. First, patients carrying the
A3243G mtDNA mutation exhibit lower insulin levels
during a hyperglycaemic clamp than non-carriers, pointing
to beta cell defect rather than peripheral insulin resistance
[13, 15]. In addition, individuals with Pearson or Kearns
Sayre syndromes due to large deletions in mtDNA exhibit
an insulin-deficient diabetes phenotype [38, 39]. Second,
transgenic mice lacking expression of the mitochondrial
genome specifically in beta cells are diabetic with poor islet
insulin release in response to glucose [40]. Third, mito-
chondrial DNA-depleted cellular models are glucose-unre-
sponsive and defective in mitochondrial function [41–43].
These models illustrate the fragility of nutrient-stimulated
insulin secretion, caused primarily by defective mitochon-
drial metabolism. What is missing among these lines of
evidence is a demonstration of the effects of the A3243G
mtDNA mutation on cellular functions required for metab-
olism-secretion coupling. Our results show the dramatic
consequences of such a patient-derived mutation on
glucose-induced mitochondrial metabolism. Future studies
should directly investigate the effects of the mutation on
glucose-stimulated insulin secretion.
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